Table 3.
Glucocorticoids-related Comorbidities Assessed at End of Follow-up
| IBCDT n = 30 | MMF n = 20 | CYC n = 10 | P | |
|---|---|---|---|---|
| Osteopenia/osteoporosis, n (%)a | 2 (7) | 4 (20) | 2 (20) | 0.31 |
| Diabetes, n (%) | 1 (3) | 4 (20) | 1 (10) | 0.16 |
| Glaucoma, n (%) | 1 (3) | 4 (20) | 3 (30) | 0.055 |
| IBCDT n = 30 | MMF and CYC n = 30 | P | |
|---|---|---|---|
| Osteopenia/osteoporosis, n (%)a | 2 (7) | 6 (20) | 0.12 |
| Diabetes, n (%) | 1 (3) | 5 (17) | 0.08 |
| Glaucoma, n (%) | 1 (3) | 7 (23) | 0.022 |
CYC, cyclophosphamide; IBCDT, intensified B-cell depletion induction therapy; MMF, mycophenolate mofetil.
a
As assessed by bone density scan (dual-energy X-ray absorptiometry scan).